首页 | 本学科首页   官方微博 | 高级检索  
     检索      

含吲哚的吡唑并[3,4-d]嘧啶衍生物的设计合成及其生物活性研究
引用本文:孙晓阳,冯思冉,董金娇,冯佳佳,刘振明,宋亚丽,乔晓强.含吲哚的吡唑并[3,4-d]嘧啶衍生物的设计合成及其生物活性研究[J].有机化学,2020(2):391-397.
作者姓名:孙晓阳  冯思冉  董金娇  冯佳佳  刘振明  宋亚丽  乔晓强
作者单位:河北大学药学院河北省药物质量分析控制重点实验室;沧州市中心医院国家药物临床试验机构;北京大学药学院天然药物及仿生药物国家重点实验室药物设计中心;河北大学药物化学与分子诊断教育部重点实验室
基金项目:河北省自然科学基金(No.B2018201269);河北省高等学校科学技术研究项目(No.ZD2019060);国家自然科学基金(No.21675039);河北省青年拔尖人才资助项目.
摘    要:利用药物设计中的生物活性基团拼接原理,设计合成了13个含吲哚的吡唑并3,4-d]嘧啶衍生物.目标化合物均经核磁共振氢谱(1H NMR)、核磁共振碳谱(13C NMR)和高分辨质谱仪(HRMS)进行了结构确证.对4株肿瘤细胞(HeLa、MGC-803、MCF-7、BEL-7404)的体外抗增殖活性实验结果表明,目标化合物均表现出一定的抗肿瘤活性,MCF-7、MGC-803肿瘤细胞株敏感度高于HeLa和BEL-7404.其中, 6-(6-甲氧羰基吲哚-3-基)硫基]-1-苯基-吡唑并3,4-d]嘧啶-4-酮(5m)表现出较好的体外肿瘤抑制活性,对MCF-7、MGC-80和HeLa细胞的IC50均小于30μmol·L^-1,对MCF-7的IC50值为(4.02±0.92)μmol·L^-1,优于对照药物依托泊苷(10.1±0.62μmol·L^-1)和羟喜树碱(5.93±0.56μmol·L^-1).拓扑异构酶抑制实验结果表明,此类化合物对TopoII有选择性抑制活性,所有化合物对TopoⅡ表现出不同程度抑制活性,对Topo Ⅰ未表现出抑制活性.

关 键 词:吲哚  吡唑并[3  4-d]嘧啶  抗肿瘤  拓扑异构酶  分子对接

Design,Synthesis and Biological Activity of Pyrazolo[3,4-d]pyrimidine Derivatives Containing Indole Moiety
Sun Xiaoyang,Feng Siran,Dong Jinjiao,Feng Jiajia,Liu Zhenming,Song Yali,Qiao Xiaoqiang.Design,Synthesis and Biological Activity of Pyrazolo[3,4-d]pyrimidine Derivatives Containing Indole Moiety[J].Chinese Journal of Organic Chemistry,2020(2):391-397.
Authors:Sun Xiaoyang  Feng Siran  Dong Jinjiao  Feng Jiajia  Liu Zhenming  Song Yali  Qiao Xiaoqiang
Institution:(Key Laboratory of Pharmaceutical Quality Control of Hebei Province,College of Pharmacetical Sciences,Hebei University,Baoding,Hebei 071000;National Drug Clinical Trial Institution,Cangzhou Central Hospital,Cangzhou,Hebei 061000;Drug Design Center,State Key Laboratory of Natural and Biomimetic Drugs,School of Pharmaceutical Sciences,Peking University,Beijing 100191;Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education,Hebei University,Baoding,Hebei 071000)
Abstract:Based on the combination principle in drug design, thirteen pyrazolo3,4-d]pyrimidine derivatives containing indole moiety were designed and synthesized. The target compounds were confirmed by 1 H NMR, 13 C NMR and HRMS. Their in vitro cytotoxicity against four human cancer cell lines(HeLa、MGC-803、MCF-7、BEL-7404) has been investigated and most of the tested compounds displayed moderate antiproliferative activity. Especially, compound 5 m exhibited the highest level of antiproliferative activity with an IC50 value <30 μmol·L^-1 for HeLa, MGC-803 and MCF-7. IC50 value of methyl 3-((4-oxo-1-phenyl-4,5-dihydro-1 H-pyrazolo3,4-d]pyrimidin-6-yl)thio)-1 H-indole-6-carboxylate(5 m) to MCF-7 was(4.02±0.92) μmol·L^-1, which was better than etoposide(10.1±0.62 μmol·L^-1) and camptothecin(5.93±0.56 μmol·L^-1). Further b iological evaluation of these compounds suggested that these compounds showed selective inhibitory activity against Topo Ⅱ as a possible intracellular target, and all compounds didn’t show inhibitory activity against Topo Ⅰ.
Keywords:indole  pyrazolo[3  4-d]pyrimidine  anticancer  topoisomerase  molecular docking
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号